Managers / Q2 2019 · view latest →
TOBAM
CIK 0001527488 · 24/26 AVENUE DES CHAMPS ELYSEES, PARIS, 75008 · 33-153234151
Summary
Tobam reported $1.8B in U.S.-listed holdings across 123 positions for Q2 2019.
Its largest position, PSA, represents 3.5% of the portfolio.
Compared with Q1 2019, the fund opened 13 new positions and exited 28.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 82.6% · $1.5B
- REIT · 9.8% · $176M
- Other · 4.3% · $77M
- ADR · 3.4% · $60M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| QCOMQUALCOMM INC | NEW | +430.1K | 430.1K | +$33M | $33M |
| ELVANTHEM INC | NEW | +16.0K | 16.0K | +$5M | $5M |
| HEI/AHEICO CORP-CLASS A | NEW | +11.9K | 11.9K | +$1M | $1M |
| CAECAE INC | NEW | +22.3K | 22.3K | +$600,000 | $600,000 |
| BHCBAUSCH HEALTH COS INC | NEW | +9.0K | 9.0K | +$227,000 | $227,000 |
| BBBLACKBERRY LTD | NEW | +22.0K | 22.0K | +$164,000 | $164,000 |
| ASNDASCENDIS PHARMA A/S - ADR | NEW | +1.4K | 1.4K | +$157,000 | $157,000 |
| TTDTRADE DESK INC/THE -CLASS A | NEW | +600 | 600 | +$137,000 | $137,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2019
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $384M | 250 | May 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $276M | 247 | Nov 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $256M | 253 | Aug 8, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $234M | 251 | Apr 16, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $328M | 319 | Jan 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $548M | 319 | Oct 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $638M | 326 | Aug 1, 2024 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2024 | $1.1B | 377 | May 2, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $1.1B | 374 | Jan 26, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $1.2B | 376 | Oct 31, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $1.3B | 359 | Jul 31, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $1.5B | 360 | May 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $1.5B | 406 | Feb 2, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $1.4B | 430 | Nov 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1.6B | 429 | Aug 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $2.0B | 429 | Apr 25, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $2.2B | 435 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $2.4B | 429 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $2.5B | 433 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $2.4B | 427 | May 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $2.2B | 429 | Feb 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $2.0B | 424 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.6B | 143 | Aug 17, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $1.3B | 135 | May 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.6B | 116 | Feb 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.5B | 119 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.8B | 123 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $2.0B | 138 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.